Specifically, some studies suggest that SMARCA4 functions as a tumor suppressor and that mutations and low expression in this gene are associated with a poor prognosis for patients with tumors [21, 22, 23, 24], whereas the opposite conclusions have been reached in other studies [25, 26, 27]. This evidence concerns the gene SMARCA4 and neoplasm.